Related references
Note: Only part of the references are listed.Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma
Esperanza M. Algarin et al.
HAEMATOLOGICA (2020)
Mechanisms of intrinsic and acquired resistance to venetoclax in B-cell lymphoproliferative disease
Piers Blombery
LEUKEMIA & LYMPHOMA (2020)
SynergyFinder: a web application for analyzing drug combination dose-response matrix data (vol 33, pg 2431, 2017)
Aleksandr Ianevski et al.
BIOINFORMATICS (2020)
BCL-XL expression is essential for human erythropoiesis and engraftment of hematopoietic stem cells
Sehar Afreen et al.
CELL DEATH & DISEASE (2020)
Simultaneously Inhibiting BCL2 and MCL1 Is a Therapeutic Option for Patients with Advanced Melanoma
Nabanita Mukherjee et al.
CANCERS (2020)
Co-inhibition of BCL-XL and MCL-1 with selective BCL-2 family inhibitors enhances cytotoxicity of cervical cancer cell lines
Siti Fairus Abdul Rahman et al.
BIOCHEMISTRY AND BIOPHYSICS REPORTS (2020)
Dual dependence on BCL2 and MCL1 in T-cell prolymphocytic leukemia
Victoria M. Smith et al.
BLOOD ADVANCES (2020)
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
Donia M. Moujalled et al.
LEUKEMIA (2019)
Recent advances in the development of Mcl-1 inhibitors for cancer therapy
Alexander W. Hird et al.
PHARMACOLOGY & THERAPEUTICS (2019)
Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal In Vivo in Relapsed Mantle Cell Lymphoma
Dana Prukova et al.
CLINICAL CANCER RESEARCH (2019)
BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
Erinna F. Lee et al.
CELL DEATH & DISEASE (2019)
Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
Richard W. Birkinshaw et al.
NATURE COMMUNICATIONS (2019)
Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells
Warren Fiskus et al.
BLOOD CANCER JOURNAL (2019)
Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia
Piers Blombery et al.
CANCER DISCOVERY (2019)
Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting
Anne Slomp et al.
BLOOD ADVANCES (2019)
Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis
Seiji Arai et al.
CLINICAL CANCER RESEARCH (2018)
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia
Carmen D. Herling et al.
NATURE COMMUNICATIONS (2018)
A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia
Haley E. Ramsey et al.
CANCER DISCOVERY (2018)
BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines
Delphine Merino et al.
CANCER CELL (2018)
Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia
Adriana E. Tron et al.
NATURE COMMUNICATIONS (2018)
Humanized Mcl-1 mice enable accurate preclinical evaluation of MCL-1 inhibitors destined for clinical use
Margs S. Brennan et al.
BLOOD (2018)
The BH3-only proteins BIM and PUMA are not critical for the reticulocyte apoptosis caused by loss of the pro-survival protein BCL-XL
Alex R. D. Delbridge et al.
CELL DEATH & DISEASE (2017)
Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL
Kallesh D. Jayappa et al.
BLOOD ADVANCES (2017)
Bcl-2 proteins in development, health, and disease of the hematopoietic system
Matthias Kollek et al.
FEBS JOURNAL (2016)
Expression Profile of BCL-2, BCL-XL, and MCL-1 Predicts Pharmacological Response to the BCL-2 Selective Antagonist Venetoclax in Multiple Myeloma Models
Elizabeth A. Punnoose et al.
MOLECULAR CANCER THERAPEUTICS (2016)
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Andras Kotschy et al.
NATURE (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Antagonism between MCL-1 and PUMA governs stem/progenitor cell survival during hematopoietic recovery from stress
Alex R. D. Delbridge et al.
BLOOD (2015)
Haematopoietic stem cell survival and transplantation efficacy is limited by the BH3-only proteins Bim and Bmf
Verena Labi et al.
EMBO MOLECULAR MEDICINE (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML
Thanh-Trang Vo et al.
CELL (2012)
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Andrew W. Roberts et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Anti-apoptotic MCL-1 localizes to the mitochondrial matrix and couples mitochondrial fusion to respiration
Rhonda M. Perciavalle et al.
NATURE CELL BIOLOGY (2012)
The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity
Clinton J. V. Campbell et al.
BLOOD (2010)
Of mice and men: Human RNA polymerase III promoter U6 is more efficient than its murine homologue for shRNA expression from a lentiviral vector in both human and murine progenitor cells
Roland Roelz et al.
EXPERIMENTAL HEMATOLOGY (2010)
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
Wyndham H. Wilson et al.
LANCET ONCOLOGY (2010)
The landscape of somatic copy-number alteration across human cancers
Rameen Beroukhim et al.
NATURE (2010)
MCL-1ES, a novel variant of MCL-1, associates with MCL-1L and induces mitochondrial cell death
Jae-Hong Kim et al.
FEBS LETTERS (2009)
Discovery of an Orally Bioavailable Small Molecule Inhibitor of Prosurvival B-Cell Lymphoma 2 Proteins
Cheol-Min Park et al.
JOURNAL OF MEDICINAL CHEMISTRY (2008)
BH3-only proteins in cell death initiation, malignant disease and anticancer therapy
V. Labi et al.
CELL DEATH AND DIFFERENTIATION (2006)
Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival
S Wuillème-Toumi et al.
LEUKEMIA (2005)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells
JT Opferman et al.
SCIENCE (2005)
MCL-1S, a splicing variant of the antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the BH3 domain
J Bae et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2000)
Share Paper
